The incidence of IH associated with CTLA-4 inhibitor and PD-1/PD-L1 inhibitor monotherapy is much lower than that of combination therapy, accounting for 5% and 1%, respectively [26,29]. Here, CTLA4 is linked to isolated hemihyperplasia.